Drugs / STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05321940 | Nov 2023 → Nov 2025 | acute lymphoblastic leukemia, acute myeloid leukemia, adult T-cell leukemia/lymphoma | Juan C. Ramos, MD | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05321940 ↗ |
| Action | Activate | “STING-dependent innate immune agonists” NCT05321940 ↗ |
| Modality | Cell therapy | “Autologous human ultraviolet (UV)-irradiated (dead) leukemia cells loaded with STAVs administered via intravenous injection.” NCT05321940 ↗ |
| Route | Intravenous | “administered via intravenous injection” NCT05321940 ↗ |